Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study

医学 特立帕肽 内科学 危险系数 骨质疏松症 四分位间距 狼牙棒 队列 物理疗法
作者
Felicia Cosman,C Cooper,Yamei Wang,Bruce H. Mitlak,S Varughese,Setareh A. Williams
出处
期刊:Osteoporosis International [Springer Nature]
标识
DOI:10.1007/s00198-022-06413-y
摘要

Mini abstractReal-world evidence on the comparative effectiveness and safety of abaloparatide versus teriparatide in women with osteoporosis may help inform treatment decisions. Following 18 months of treatment, abaloparatide was comparable to teriparatide for prevention of nonvertebral fractures, resulted in a 22% risk reduction for hip fractures, and demonstrated similar cardiovascular safety. SummaryOsteoporotic fracture risk can be reduced with anabolic or antiresorptive medications. In addition to efficacy and safety data from controlled clinical trials, real-world evidence on comparative effectiveness and safety may help inform treatment decisions.IntroductionThe real-world effectiveness of abaloparatide versus teriparatide on nonvertebral fracture (NVF) incidence and cardiovascular safety during the 19-month period after treatment initiation were evaluated (NCT04974723).MethodsAnonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy. Most were enrolled in commercial and Medicare health plans. Index was the date of the initial prescription dispensed during the identification period. In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model.ResultsPropensity score matching yielded 11,616 patients per cohort. Overall median age (interquartile range) was 67 (61, 75) years, and 25.6% had a fracture history. Over 19 months, 335 patients on abaloparatide and 375 on teriparatide had a NVF (hazard ratio [95% confidence interval]: 0.89 [0.77, 1.03]), and 121 and 154 patients, respectively, had a hip fracture [HR (95% CI): 0.78 (0.62, 1.00)]. The MACE and MACE + HF rates were similar between cohorts.ConclusionsFollowing 18 months of treatment, abaloparatide was comparable to teriparatide for prevention of NVF and similar cardiovascular safety was demonstrated between cohorts.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阿里山完成签到,获得积分10
2秒前
花生了什么树完成签到 ,获得积分10
2秒前
村口的帅老头完成签到 ,获得积分10
2秒前
科研狗完成签到 ,获得积分10
3秒前
柳绿柳完成签到,获得积分20
5秒前
许大脚完成签到 ,获得积分10
6秒前
精明寒松完成签到 ,获得积分10
7秒前
wsl完成签到 ,获得积分10
7秒前
执着夏岚完成签到 ,获得积分10
12秒前
njseu完成签到 ,获得积分10
12秒前
kangshuai完成签到,获得积分10
12秒前
一一完成签到,获得积分10
13秒前
car子完成签到 ,获得积分10
13秒前
stokis03完成签到 ,获得积分10
16秒前
wqc2060完成签到,获得积分10
17秒前
和平使命应助科研通管家采纳,获得10
20秒前
xiaoli完成签到,获得积分10
20秒前
薰硝壤应助科研通管家采纳,获得10
20秒前
24秒前
Likz完成签到,获得积分10
26秒前
home完成签到,获得积分10
26秒前
LIKUN完成签到,获得积分10
29秒前
傲娇凉面发布了新的文献求助30
30秒前
YC发布了新的文献求助10
31秒前
学习完成签到,获得积分10
31秒前
ming完成签到,获得积分10
37秒前
我爱学习呢完成签到,获得积分10
38秒前
美好乐松完成签到,获得积分10
41秒前
清爽玉米完成签到,获得积分10
41秒前
43秒前
神说要有光完成签到 ,获得积分10
44秒前
cctv18应助傲娇凉面采纳,获得10
45秒前
cctv18应助傲娇凉面采纳,获得30
45秒前
酷炫书芹应助请叫我鬼才采纳,获得10
46秒前
nuonuomimi完成签到,获得积分10
46秒前
黄橙子完成签到 ,获得积分10
50秒前
指尖心事完成签到,获得积分10
51秒前
寻道图强应助风中的蘑菇采纳,获得30
51秒前
何睦完成签到 ,获得积分10
51秒前
非主流的毛线完成签到,获得积分10
55秒前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052675
求助须知:如何正确求助?哪些是违规求助? 2709898
关于积分的说明 7418335
捐赠科研通 2354494
什么是DOI,文献DOI怎么找? 1246139
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921